Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons by Naseema Gangat, Ayalew Tefferi

Get full text

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days by Naseema Gangat, Ayalew Tefferi

Get full text

Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative n... by Ali Alsugair, Saubia Fathima, Fnu Aperna, Naseema Gangat, Ayalew Tefferi

Get full text

<i>CSF3R</i> mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends by Abiola Bolarinwa, Natasha Szuber, Rong He, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Get full text

Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates by Sarah Dingli, Saubia Fathima, Priyansh Faldu, Naseema Gangat, David Dingli, Ayalew Tefferi

Get full text

Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases by Moazah Iftikhar, Masooma Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren Reichard, Cinthya Zepeda Mendoza, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Get full text

Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis by Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Francesca Fenili, Maria Chiara Finazzi, Marta Castelli, Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi

Get full text

Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials by Maymona Abdelmagid, Jeanne M. Palmer, Aref Al-Kali, Mehrdad Hefazi, James Foran, Kebede H. Begna, Cecilia Y. Arana Yi, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Get full text

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy by Isla M. Johnson, Rimal Ilyas, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek Mangaonkar, Antoine Saliba, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat

Get full text

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations by Anmol Baranwal, Kimberly J. Langer, Vedavyas Gannamani, Danielle Rud, Alia Cibich, Caner Saygin, Mariam Nawas, Talha Badar, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Vivek Roy, James M. Foran, Hemant S. Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Z. Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek Mangaonkar, William Hogan, Mark Litzow, Hassan Alkhateeb, Ayalew Tefferi, Chung Hoow Kok, Guru Subramanian Guru Murthy, Anand Patel, Ashish Bajel, Devendra K. Hiwase, Mithun Vinod Shah

Get full text

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent internation... by Mithun Vinod Shah, Kevin Hung, Anmol Baranwal, Gauri Wechalekar, Aref Al-Kali, Carla R. Toop, Patricia Greipp, Monika M. Kutyna, Aasiya Matin, Dariusz Ladon, Antoine Saliba, Dong Chen, Kebede Begna, Anna Brown, Danielle Rud, Mark R. Litzow, William J. Hogan, Peter Bardy, Talha Badar, Sharad Kumar, David T. Yeung, Mrinal M. Patnaik, James M. Foran, Rong He, Naseema Gangat, Mehrdad Hefazi, Hamish S. Scott, Cecilia Y. Arana Yi, Hassan Alkhateeb, Abhishek A. Mangaonkar, Daniel Thomas, Christopher N. Hahn, Attilio Orazi, Daniel A. Arber, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase

Get full text